.png){kind=icon}
.png){kind=icon}
Return
PROTAC-Mediated DPP-4 Degradation: A New Solution for Type 2 Diabetes
.png){kind=icon}
PRE
AI
W
DOI：10.1021/acs.jmedchem.6c01141.png)
.png){kind=icon}
Original request for help.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
Dipeptidyl peptidase-4 (DPP-4) is an important aggravating factor in the progression and exacerbation of type 2 diabetes mellitus (T2DM), a condition characterized by diminished insulin responsiveness because it rapidly degrades glucagon-like peptide-1 (GLP-1) and other peptide with similar physiological function. Although several small-molecule DPP-4 inhibitors have been developed for the clinical management of T2DM, their therapeutic benefits are only moderate, as the fail to achieve for sustained inhibition of DPP-4. Hence, targeted degradation of DPP-4 using proteolysis-targeting chimera (PROTAC) technology offers an alternative strategy for sustained glycemic control in T2DM.
Journal
IF:
6.8
Papers:
2.7W
Citations:
9.4W
Organization
Cited Papers